Ari Daniels
Psychiatric/Mental Health · Marlton, NJNPI 1497421853
Payments from drug & device makers
Across 249 payments — averaging $12.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$767
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
- Alkermes, Inc.$364
- Otsuka America Pharmaceutical, Inc.$208
- Takeda Pharmaceuticals U.S.A., Inc.$174
- Vanda Pharmaceuticals Inc.$169
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,16998%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 56 | $767 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $529 |
| Alkermes, Inc. | 33 | $364 |
| Otsuka America Pharmaceutical, Inc. | 14 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $174 |
| Vanda Pharmaceuticals Inc. | 12 | $169 |
| Lundbeck LLC | 11 | $163 |
| Corium, LLC | 17 | $141 |
| Almatica Pharma LLC | 9 | $130 |
| Sunovion Pharmaceuticals Inc. | 7 | $125 |
| Teva Pharmaceuticals USA, Inc. | 7 | $102 |
| Neurocrine Biosciences, Inc. | 6 | $91 |
| Axsome Therapeutics, Inc. | 4 | $66 |
| Idorsia Pharmaceuticals US Inc | 4 | $59 |
| Noven Therapeutics, LLC | 4 | $56 |
| OWP Pharmaceuticals, Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $17 |
| Bausch Health US, LLC | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,228 in reported general payments places this provider in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 14 | $90,200 |
| VraylarCariprazine Hcl | 17 | $29,968 |
| RexultiBrexpiprazole | 14 | $18,322 |
| Lurasidone Hcl | 36 | $8,934 |
| Clozapine OdtClozapine | 12 | $6,327 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,974 |
| Chlorpromazine Hcl | 12 | $4,469 |
| Aripiprazole | 49 | $3,713 |
| Clorazepate Dipotassium | 12 | $3,372 |
| Asenapine Maleate | 23 | $2,693 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 73 | $2,329 |
| Quetiapine Fumarate | 105 | $2,133 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $2,042 |
| Perphenazine | 18 | $1,952 |
| Bupropion XlBupropion Hcl | 50 | $1,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $102 | $90,20014 claims |
| AbbVieVraylar | $767 | $29,96817 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $208 | $18,32214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $174 | $5,97411 claims |
| Almatica Pharma LLCSertraline Hcl | $130 | $48059 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Marlton
- Ubong UdofiaMarlton$407K
- Aaron SpectorMarlton$100K
- Regina GarbarinoMarlton$12K
- Stella OkahMarlton$7K
- Anthony DimuraRed Bank$130K
- Amy PinsenNewton$111K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.